Skip to main content
Hans C. Lee on Muck Rack

Hans C. Lee

As seen in: Bloomberg News, Nature, Wiley, Wiley Online Library, Yahoo Finance, Sydney Morning Herald, Taylor & Francis Online, Mint, The Sunday Age, Haaretz and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hans C.

Contact Hans C., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma

|
By Naresh Bumma, Hans C. Lee, Joshua Richter
| Taylor & Francis Online
Abstract Objective Assessing the comparative efficacy of novel chimeric antigen receptor T-cell (CAR-T) and bispecific antibody (bsAb) therapies for relapsed/refractory multiple myeloma (RRMM) is crucial for informed treatment decisions. This study systematically reviewed indirect treatment comparisons (ITCs) evaluating the efficacy of approved CAR-T therapies and bsAbs in triple-class exposed RRMM.
Open in Who Shared Issue with article?

Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010–2020

|
By Ben Lerman, Stefan O. Schönland, Ute Hegenbart, Vaishali Sanchorawala, Hamza Hassan, Hans C. Lee, Muzaffar H. Qazilbash, Andrew Kin, Jeffrey Zonder, Angela Dispenzieri, David Dingli, Francis K Buadi, Sally Arai, Michelle Chin, Rajshekhar Chakraborty, Markus Y. Mapara, Suzanne Lentzsch, Hila Magen, Eden Shkury, Heather Landau, Morie A Gertz, Eli Muchtar, Caitlin Sarubbi
| Nature Verified
Abstract The role of autologous stem cell transplantation (ASCT) is central in AL amyloidosis and continues to be defined in the era of newer therapies. To evaluate contemporary patient selection, practice patterns, and outcomes, we conducted a retrospective, multicenter study across nine tertiary referral centers, including 1047 patients with AL amyloidosis who underwent ASCT between 2010 and 2020.
Open in Who Shared Issue with article?

D-VRD induction and autologous transplant in patients ≥70 years

|
By Oren Pasvolsky, Curtis Marcoux, Denái R. Milton, Mark Tanner, Qaiser Bashir, Samer Srour, Neeraj K. Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Yosra M. Aljawai, Asad Haider, Hans C. Lee, Partow Kebriaei, Sheeba K. Thomas, Robert Orlowski, Richard Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Muhammad Bilal Islam
| Nature Verified
Dear Editor, The addition of daratumumab to triplet induction regimens has significantly improved depth of response and progression-free survival (PFS) in newly diagnosed multiple myeloma (MM), as demonstrated in the GRIFFIN and PERSEUS trials, both of which evaluated daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRD) induction followed by autologous hematopoietic cell transplantation (autoHCT) [1, 2].
Open in Who Shared Issue with article?
See all 81 licensed articles (131 Total)